Cytomx Therapeutics, INC. (CTMX) — 8-K Filings

8-K Filings (12)

• CytomX Therapeutics Files 8-K — Aug 13, 2025 Risk: low
  On August 13, 2025, CytomX Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and is no
• CytomX Therapeutics Files 8-K on Officer/Director Changes — Jun 13, 2025 Risk: medium
  CytomX Therapeutics, Inc. filed an 8-K on June 13, 2025, reporting on events that occurred on June 11, 2025. The filing covers the departure of directors or cer
• CytomX Therapeutics Files 8-K — May 28, 2025 Risk: low
  CytomX Therapeutics, Inc. filed an 8-K on May 28, 2025, reporting an event on May 27, 2025. The filing is categorized under 'Other Events' and does not specify
• CytomX Therapeutics Files 8-K — May 13, 2025 Risk: low
  CytomX Therapeutics, Inc. filed an 8-K on May 13, 2025, reporting other events and financial statements. The filing date indicates the report was submitted on M
• CytomX Therapeutics Files 8-K on Financials and Operations — May 12, 2025 Risk: low
  CytomX Therapeutics, Inc. filed an 8-K on May 12, 2025, reporting on its results of operations and financial condition, as well as other events. The filing also
• CytomX Therapeutics Faces Listing Rule Issues — Feb 26, 2025 Risk: high
  CytomX Therapeutics, Inc. filed an 8-K on February 26, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with th
• CytomX Therapeutics Appoints New CMO, CSO, and Directors — Feb 3, 2025 Risk: medium
  CytomX Therapeutics, Inc. announced on January 30, 2025, changes in its executive and director roles. Dr. Sean E. MacLeod has been appointed as the new Chief Me
• CytomX Therapeutics Reports Exit/Disposal Costs — Jan 6, 2025 Risk: medium
  CytomX Therapeutics, Inc. filed an 8-K on January 6, 2025, to report on cost associated with exit or disposal activities. The filing does not contain specific d
• CytomX Therapeutics Announces Board and Executive Changes — Jun 17, 2024 Risk: low
  CytomX Therapeutics, Inc. announced on June 12, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departur
• CytomX Therapeutics Files 8-K on Corporate Matters — May 17, 2024 Risk: low
  CytomX Therapeutics, Inc. filed an 8-K on May 17, 2024, reporting on events that occurred on May 15, 2024. The filing indicates a change in the company's fiscal
• CytomX Therapeutics Files 8-K — May 8, 2024 Risk: low
  CytomX Therapeutics, Inc. filed an 8-K on May 8, 2024, reporting other events and financial statements. The filing details the company's principal executive off
• CytomX Therapeutics Announces Board and Executive Changes — Mar 22, 2024 Risk: low
  CytomX Therapeutics, Inc. announced on March 20, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Steven D. Agger was appoi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX